New findings show durable anti-tumor activity with KEYTRUDAź (pembrolizumab)
Merck announced new investigational data evaluating KEYTRUDAź (pembrolizumab) as a monotherapy from the KEYNOTE-012 Phase 1b study in 132 pre-treated patients with metastatic head and neck cancer. The ORR was 24.8 percent for KEYTRUDA (200 mg fixed dose every three weeks). May 29, 2015